Pub Date : 2025-02-25DOI: 10.1016/s2213-8587(25)00035-x
No Abstract
{"title":"Thank you to The Lancet Diabetes & Endocrinology's statistical and peer reviewers in 2024","authors":"","doi":"10.1016/s2213-8587(25)00035-x","DOIUrl":"https://doi.org/10.1016/s2213-8587(25)00035-x","url":null,"abstract":"No Abstract","PeriodicalId":48790,"journal":{"name":"The Lancet Diabetes & Endocrinology","volume":"32 1","pages":""},"PeriodicalIF":44.5,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143495818","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-25DOI: 10.1016/s2213-8587(25)00006-3
Rubino F, Cummings DE, Eckel RH, et al. Definition and diagnostic criteria of clinical obesity. Lancet Diabetes Endocrinol 2025; 13: 221–62—In this Commission, “Malaysian Association for the Study of Obesity (MASO) | Malaysia”, “Obesity Canada | Canada”, and “Sociedade Brasileira de Endocrinologia e Metabolismo (SBEM) | Brasil” should be present in Appendix 2 (Appendix 2.1 Table 1. Organisations that have endorsed the consensus statements of the commission), and the rest of the table subsequently renumbered. Consequently, the final sentence of the Executive summary in the Commission should say “endorsed by more than 75 organisations worldwide”. A Korean translation has been added to Appendix 1 and thus the list of translation languages for the Commission should be “Arabic, Chinese, French, German, Greek, Hindi, Italian, Japanese, Korean, Polish, Portuguese, Spanish, and Swedish”. These corrections have been made to the online version as of Feb 25, 2025, and the printed version is correct.
{"title":"Correction to Lancet Diabetes Endocrinol 2025; 13: 221–62","authors":"","doi":"10.1016/s2213-8587(25)00006-3","DOIUrl":"https://doi.org/10.1016/s2213-8587(25)00006-3","url":null,"abstract":"<em>Rubino F, Cummings DE, Eckel RH, et al. Definition and diagnostic criteria of clinical obesity.</em> Lancet Diabetes Endocrinol <em>2025; <strong>13:</strong> 221–62</em>—In this Commission, “Malaysian Association for the Study of Obesity (MASO) | Malaysia”, “Obesity Canada | Canada”, and “Sociedade Brasileira de Endocrinologia e Metabolismo (SBEM) | Brasil” should be present in Appendix 2 (Appendix 2.1 Table 1. Organisations that have endorsed the consensus statements of the commission), and the rest of the table subsequently renumbered. Consequently, the final sentence of the Executive summary in the Commission should say “endorsed by more than 75 organisations worldwide”. A Korean translation has been added to Appendix 1 and thus the list of translation languages for the Commission should be “Arabic, Chinese, French, German, Greek, Hindi, Italian, Japanese, Korean, Polish, Portuguese, Spanish, and Swedish”. These corrections have been made to the online version as of Feb 25, 2025, and the printed version is correct.","PeriodicalId":48790,"journal":{"name":"The Lancet Diabetes & Endocrinology","volume":"49 1","pages":""},"PeriodicalIF":44.5,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143495819","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-25DOI: 10.1016/s2213-8587(25)00030-0
Jennifer Manne-Goehler, Rosamund Lewis, Bianca Hemmingsen
No Abstract
{"title":"Mpox and diabetes: a needed public health research agenda","authors":"Jennifer Manne-Goehler, Rosamund Lewis, Bianca Hemmingsen","doi":"10.1016/s2213-8587(25)00030-0","DOIUrl":"https://doi.org/10.1016/s2213-8587(25)00030-0","url":null,"abstract":"No Abstract","PeriodicalId":48790,"journal":{"name":"The Lancet Diabetes & Endocrinology","volume":"24 1","pages":""},"PeriodicalIF":44.5,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143495822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-21DOI: 10.1016/s2213-8587(24)00348-6
David A Jolliffe, Carlos A Camargo, John D Sluyter, Mary Aglipay, John F Aloia, Peter Bergman, Heike A Bischoff-Ferrari, Arturo Borzutzky, Vadim Y Bubes, Camilla T Damsgaard, Francine M Ducharme, Gal Dubnov-Raz, Susanna Esposito, Davaasambuu Ganmaa, Clare Gilham, Adit A Ginde, Inbal Golan-Tripto, Emma C Goodall, Cameron C Grant, Christopher J Griffiths, Adrian R Martineau
Background
A 2021 meta-analysis of 37 randomised controlled trials (RCTs) of vitamin D supplementation for prevention of acute respiratory infections (ARIs) revealed a statistically significant protective effect of the intervention (odds ratio [OR] 0·92 [95% CI 0·86 to 0·99]). Since then, six eligible RCTs have been completed, including one large trial (n=15 804). We aimed to re-examine the link between vitamin D supplementation and prevention of ARIs.
Methods
Updated systematic review and meta-analysis of data from RCTs of vitamin D for ARI prevention using a random effects model. Subgroup analyses were done to determine whether effects of vitamin D on risk of ARI varied according to baseline 25-hydroxyvitamin D (25[OH]D) concentration, dosing regimen, or age. We searched MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials, Web of Science, and the ClinicalTrials.gov between May 1, 2020 (end-date of search of our previous meta-analysis) and April 30, 2024. No language restrictions were imposed. Double-blind RCTs supplementing vitamin D for any duration, with placebo or lower-dose vitamin D control, were eligible if approved by a Research Ethics Committee and if ARI incidence was collected prospectively and pre-specified as an efficacy outcome. Aggregate data, stratified by baseline 25(OH)D concentration and age, were obtained from study authors. The study was registered with PROSPERO (no. CRD42024527191).
Findings
We identified six new RCTs (19 337 participants). Data were obtained for 16 085 (83·2%) participants in three new RCTs and combined with data from 48 488 participants in 43 RCTs identified in our previous meta-analysis. For the primary comparison of any vitamin D versus placebo, the intervention did not statistically significantly affect overall ARI risk (OR 0·94 [95% CI 0·88–1·00], p=0·057; 40 studies; 61 589 participants; I2=26·4%). Pre-specified subgroup analysis did not reveal evidence of effect modification by age, baseline vitamin D status, dosing frequency, or dose size. Vitamin D did not influence the proportion of participants experiencing at least one serious adverse event (OR 0·96 [95% CI 0·90–1·04]; 38 studies; I2=0·0%). A funnel plot showed left-sided asymmetry (p=0·0020, Egger's test).
Interpretation
This updated meta-analysis yielded a similar point estimate for the overall effect of vitamin D supplementation on ARI risk to that obtained previously, but the 95% CI for this effect estimate now includes 1·00, indicating no statistically significant protection.
Funding
None.
{"title":"Vitamin D supplementation to prevent acute respiratory infections: systematic review and meta-analysis of stratified aggregate data","authors":"David A Jolliffe, Carlos A Camargo, John D Sluyter, Mary Aglipay, John F Aloia, Peter Bergman, Heike A Bischoff-Ferrari, Arturo Borzutzky, Vadim Y Bubes, Camilla T Damsgaard, Francine M Ducharme, Gal Dubnov-Raz, Susanna Esposito, Davaasambuu Ganmaa, Clare Gilham, Adit A Ginde, Inbal Golan-Tripto, Emma C Goodall, Cameron C Grant, Christopher J Griffiths, Adrian R Martineau","doi":"10.1016/s2213-8587(24)00348-6","DOIUrl":"https://doi.org/10.1016/s2213-8587(24)00348-6","url":null,"abstract":"<h3>Background</h3>A 2021 meta-analysis of 37 randomised controlled trials (RCTs) of vitamin D supplementation for prevention of acute respiratory infections (ARIs) revealed a statistically significant protective effect of the intervention (odds ratio [OR] 0·92 [95% CI 0·86 to 0·99]). Since then, six eligible RCTs have been completed, including one large trial (n=15 804). We aimed to re-examine the link between vitamin D supplementation and prevention of ARIs.<h3>Methods</h3>Updated systematic review and meta-analysis of data from RCTs of vitamin D for ARI prevention using a random effects model. Subgroup analyses were done to determine whether effects of vitamin D on risk of ARI varied according to baseline 25-hydroxyvitamin D (25[OH]D) concentration, dosing regimen, or age. We searched MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials, Web of Science, and the <span><span>ClinicalTrials.gov</span><svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"><path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"></path></svg></span> between May 1, 2020 (end-date of search of our previous meta-analysis) and April 30, 2024. No language restrictions were imposed. Double-blind RCTs supplementing vitamin D for any duration, with placebo or lower-dose vitamin D control, were eligible if approved by a Research Ethics Committee and if ARI incidence was collected prospectively and pre-specified as an efficacy outcome. Aggregate data, stratified by baseline 25(OH)D concentration and age, were obtained from study authors. The study was registered with PROSPERO (no. CRD42024527191).<h3>Findings</h3>We identified six new RCTs (19 337 participants). Data were obtained for 16 085 (83·2%) participants in three new RCTs and combined with data from 48 488 participants in 43 RCTs identified in our previous meta-analysis. For the primary comparison of any vitamin D versus placebo, the intervention did not statistically significantly affect overall ARI risk (OR 0·94 [95% CI 0·88–1·00], p=0·057; 40 studies; 61 589 participants; I<sup>2</sup>=26·4%). Pre-specified subgroup analysis did not reveal evidence of effect modification by age, baseline vitamin D status, dosing frequency, or dose size. Vitamin D did not influence the proportion of participants experiencing at least one serious adverse event (OR 0·96 [95% CI 0·90–1·04]; 38 studies; I<sup>2</sup>=0·0%). A funnel plot showed left-sided asymmetry (p=0·0020, Egger's test).<h3>Interpretation</h3>This updated meta-analysis yielded a similar point estimate for the overall effect of vitamin D supplementation on ARI risk to that obtained previously, but the 95% CI for this effect estimate now includes 1·00, indicating no statistically significant protection.<h3>Funding</h3>None.","PeriodicalId":48790,"journal":{"name":"The Lancet Diabetes & Endocrinology","volume":"47 1","pages":""},"PeriodicalIF":44.5,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143470994","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-21DOI: 10.1016/s2213-8587(25)00051-8
Eckard AR, Wu Q, Sattar A, et al. Once-weekly semaglutide in people with HIV-associated lipohypertrophy: a randomised, double-blind, placebo-controlled phase 2b single-centre clinical trial. Lancet Diabetes Endocrinol 2024; 12: 523–34—In table 1, the number of participants in the placebo group listed as currently using tenofovir alafenamide has been corrected to 37 (69%). In the second paragraph of the results section, the fourth sentence has been corrected to, “80 (74%) of participants were on tenofovir alafenamide; 66 (61%) participants were on INSTI and tenofovir alafenamide.” In table 2, the subheadings have been corrected to: ln fasting insulin, uIU/mL; ln fasting HOMA-IR; In high-density lipoprotein cholesterol, mg/dL; In very low-density lipoprotein cholesterol, mg/dL; and ln triglycerides, mg/dL. Also in table 2, for the subheading ln atherosclerotic cardiovascular disease risk estimate; the β* value has been corrected to −0·39, the SE to 0·18, the 95% CI of β to −0·74 to −0·05, the p value to 0·0264‡, and the % change† to –32·6%. In the seventh paragraph of the results section, the second sentence has been corrected to, “Diastolic blood pressure, heart rate, total cholesterol, low-density lipoprotein cholesterol, caloric intake, and physical activity did not show any statistically significant changes.” The last two sentences of the seventh paragraph of the discussion have been removed. These changes have been made to the online version as of Feb 21, 2025.
{"title":"Correction to Lancet Diabetes Endocrinol 2024; 12: 523–34","authors":"","doi":"10.1016/s2213-8587(25)00051-8","DOIUrl":"https://doi.org/10.1016/s2213-8587(25)00051-8","url":null,"abstract":"<em>Eckard AR, Wu Q, Sattar A, et al. Once-weekly semaglutide in people with HIV-associated lipohypertrophy: a randomised, double-blind, placebo-controlled phase 2b single-centre clinical trial.</em> Lancet Diabetes Endocrinol <em>2024;</em> 12: <em>523–34</em>—In table 1, the number of participants in the placebo group listed as currently using tenofovir alafenamide has been corrected to 37 (69%). In the second paragraph of the results section, the fourth sentence has been corrected to, “80 (74%) of participants were on tenofovir alafenamide; 66 (61%) participants were on INSTI and tenofovir alafenamide.” In table 2, the subheadings have been corrected to: ln fasting insulin, uIU/mL; ln fasting HOMA-IR; In high-density lipoprotein cholesterol, mg/dL; In very low-density lipoprotein cholesterol, mg/dL; and ln triglycerides, mg/dL. Also in table 2, for the subheading ln atherosclerotic cardiovascular disease risk estimate; the β* value has been corrected to −0·39, the SE to 0·18, the 95% CI of β to −0·74 to −0·05, the p value to 0·0264‡, and the % change† to –32·6%. In the seventh paragraph of the results section, the second sentence has been corrected to, “Diastolic blood pressure, heart rate, total cholesterol, low-density lipoprotein cholesterol, caloric intake, and physical activity did not show any statistically significant changes.” The last two sentences of the seventh paragraph of the discussion have been removed. These changes have been made to the online version as of Feb 21, 2025.","PeriodicalId":48790,"journal":{"name":"The Lancet Diabetes & Endocrinology","volume":"30 1","pages":""},"PeriodicalIF":44.5,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143470993","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-19DOI: 10.1016/s2213-8587(25)00031-2
Ray Wang, Mervyn Kyi, David O'Neal, Gerry Rayman, Spiros Fourlanos
No Abstract
{"title":"When glucose time in range is not tight, is it lax? Considering new terminology for CGM targets","authors":"Ray Wang, Mervyn Kyi, David O'Neal, Gerry Rayman, Spiros Fourlanos","doi":"10.1016/s2213-8587(25)00031-2","DOIUrl":"https://doi.org/10.1016/s2213-8587(25)00031-2","url":null,"abstract":"No Abstract","PeriodicalId":48790,"journal":{"name":"The Lancet Diabetes & Endocrinology","volume":"49 1","pages":""},"PeriodicalIF":44.5,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143451492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-17DOI: 10.1016/s2213-8587(24)00372-3
Medha Munshi, Anna R Kahkoska, Joshua J Neumiller, Anastasia-Stefania Alexopoulos, Nancy A Allen, Tali Cukierman-Yaffe, Elbert S Huang, Sei J Lee, Kasia J Lipska, Lisa M McCarthy, Graydon S Meneilly, Naushira Pandya, Richard E Pratley, Leocadio Rodriguez-Mañas, Alan J Sinclair, Sarah L Sy, Elena Toschi, Ruth S Weinstock
Treating older people with diabetes is challenging due to multiple medical comorbidities that might interfere with patients' ability to perform self-care. Most diabetes guidelines focus on improving glycaemia through addition of medications, but few address strategies to reduce medication burden for older adults—a concept known as deprescribing. Strategies for deprescribing might include stopping high-risk medications, decreasing the dose, or substituting for less harmful agents. Accordingly, glycaemic management strategies for older adults with type 1 and type 2 diabetes not responding to their current regimen require an understanding of how and when to realign therapy to meet patient's current needs, which represents a major clinical practice gap. With the gap in guidance on how to deprescribe or otherwise adjust therapy in older adults with diabetes in mind, the International Geriatric Diabetes Society, an organisation dedicated to improving care of older individuals with diabetes, convened a Deprescribing Consensus Initiative in May, 2023, to discuss Optimization of diabetes treatment regimens in older adults: the role of de-prescribing, de-intensification and simplification of regimens. The recommendations from this group initiative are discussed and described in this Review.
{"title":"Realigning diabetes regimens in older adults: a 4S Pathway to guide simplification and deprescribing strategies","authors":"Medha Munshi, Anna R Kahkoska, Joshua J Neumiller, Anastasia-Stefania Alexopoulos, Nancy A Allen, Tali Cukierman-Yaffe, Elbert S Huang, Sei J Lee, Kasia J Lipska, Lisa M McCarthy, Graydon S Meneilly, Naushira Pandya, Richard E Pratley, Leocadio Rodriguez-Mañas, Alan J Sinclair, Sarah L Sy, Elena Toschi, Ruth S Weinstock","doi":"10.1016/s2213-8587(24)00372-3","DOIUrl":"https://doi.org/10.1016/s2213-8587(24)00372-3","url":null,"abstract":"Treating older people with diabetes is challenging due to multiple medical comorbidities that might interfere with patients' ability to perform self-care. Most diabetes guidelines focus on improving glycaemia through addition of medications, but few address strategies to reduce medication burden for older adults—a concept known as deprescribing. Strategies for deprescribing might include stopping high-risk medications, decreasing the dose, or substituting for less harmful agents. Accordingly, glycaemic management strategies for older adults with type 1 and type 2 diabetes not responding to their current regimen require an understanding of how and when to realign therapy to meet patient's current needs, which represents a major clinical practice gap. With the gap in guidance on how to deprescribe or otherwise adjust therapy in older adults with diabetes in mind, the International Geriatric Diabetes Society, an organisation dedicated to improving care of older individuals with diabetes, convened a Deprescribing Consensus Initiative in May, 2023, to discuss Optimization of diabetes treatment regimens in older adults: the role of de-prescribing, de-intensification and simplification of regimens. The recommendations from this group initiative are discussed and described in this Review.","PeriodicalId":48790,"journal":{"name":"The Lancet Diabetes & Endocrinology","volume":"64 1","pages":""},"PeriodicalIF":44.5,"publicationDate":"2025-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143435485","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-17DOI: 10.1016/s2213-8587(25)00032-4
Zimmermann AT, Lanzinger S, Kummernes SJ, et al. Treatment regimens and glycaemic outcomes in more than 100 000 children with type 1 diabetes (2013–22): a longitudinal analysis of data from paediatric diabetes registries. Lancet Diabetes Endocrinol 2025; 13: 47–56—The appendix of this Article has been corrected as of Feb 17, 2025.
{"title":"Correction to Lancet Diabetes Endocrinol 2025; 13: 47–56","authors":"","doi":"10.1016/s2213-8587(25)00032-4","DOIUrl":"https://doi.org/10.1016/s2213-8587(25)00032-4","url":null,"abstract":"<em>Zimmermann AT, Lanzinger S, Kummernes SJ, et al. Treatment regimens and glycaemic outcomes in more than 100 000 children with type 1 diabetes (2013–22): a longitudinal analysis of data from paediatric diabetes registries.</em> Lancet Diabetes Endocrinol <em>2025;</em> 13: <em>47–56</em>—The appendix of this Article has been corrected as of Feb 17, 2025.","PeriodicalId":48790,"journal":{"name":"The Lancet Diabetes & Endocrinology","volume":"62 1","pages":""},"PeriodicalIF":44.5,"publicationDate":"2025-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143434935","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：